期刊文献+

Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma 被引量:1

Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma
下载PDF
导出
摘要 AIM:To examine surgical and medical outcomes for patients with cholangiocarcinoma using a populationbased cancer registry.METHODS:Using the California Cancer Registry's Cancer Surveillance Program,patients with intrahepatic cholangiocarcinoma treated in Los Angeles County from 1988 to 2006 were identified and evaluated for clinical and pathologic factors and therapies received(surgery,radiation,and chemotherapy).The surgical cohort was further categorized into three treatment groups:patients who received adjuvant chemotherapy,adjuvant chemoradiation,or underwent surgery alone(no chemotherapy or radiation administered).Survival was assessed by Kaplan-Meier method;and Cox proportional hazard modeling was used in multivariate analysis.RESULTS:Of 825 patients,60.2% received no treatment.Of the remaining 328 patients,18.5% chemotherapy only,7.4% chemoradiation,and 13.8% underwent surgery.More male patients underwent surgical resection(P = 0.004).Surgical patients were younger than the patients receiving chemotherapy or chemoradiation(P < 0.001).Of the surgical cohort(n = 114),60.5% underwent surgery alone while 39.5% underwent surgery plus adjuvant therapy(chemotherapy n = 20;chemoradiation,n = 21)(P < 0.001).Median survival for all patients in the study was 6.6 mo.Median survival was highest for patients who underwent surgery(23 mo),whereas both chemotherapy(9 mo) and chemoradiation(8 mo) alone were each less effective(P < 0.001).By multivariate analysis,extent of disease,receipt of surgery,and administration of chemotherapy(with/without surgery) were independent predictors of overall survival.CONCLUSION:This study demonstrates that surgery is a critical treatment modality.Multimodality treatment has yet to be standardized,but play a role in optimal therapy for cholangiocarcinoma. AIM:To examine surgical and medical outcomes for patients with cholangiocarcinoma using a populationbased cancer registry.METHODS:Using the California Cancer Registry’s Cancer Surveillance Program,patients with intrahepatic cholangiocarcinoma treated in Los Angeles County from 1988 to 2006 were identified and evaluated for clinical and pathologic factors and therapies received(surgery,radiation,and chemotherapy).The surgical cohort was further categorized into three treatment groups:patients who received adjuvant chemotherapy,adjuvant chemoradiation,or underwent surgery alone(no chemotherapy or radiation administered).Survival was assessed by Kaplan-Meier method;and Cox proportional hazard modeling was used in multivariate analysis.RESULTS:Of 825 patients,60.2% received no treatment.Of the remaining 328 patients,18.5% chemotherapy only,7.4% chemoradiation,and 13.8% underwent surgery.More male patients underwent surgical resection(P = 0.004).Surgical patients were younger than the patients receiving chemotherapy or chemoradiation(P &lt; 0.001).Of the surgical cohort(n = 114),60.5% underwent surgery alone while 39.5% underwent surgery plus adjuvant therapy(chemotherapy n = 20;chemoradiation,n = 21)(P &lt; 0.001).Median survival for all patients in the study was 6.6 mo.Median survival was highest for patients who underwent surgery(23 mo),whereas both chemotherapy(9 mo) and chemoradiation(8 mo) alone were each less effective(P &lt; 0.001).By multivariate analysis,extent of disease,receipt of surgery,and administration of chemotherapy(with/without surgery) were independent predictors of overall survival.CONCLUSION:This study demonstrates that surgery is a critical treatment modality.Multimodality treatment has yet to be standardized,but play a role in optimal therapy for cholangiocarcinoma.
出处 《World Journal of Gastrointestinal Surgery》 SCIE CAS 2013年第6期178-186,共9页 世界胃肠外科杂志(英文版)(电子版)
关键词 CHOLANGIOCARCINOMA CHEMOTHERAPY SURGERY SURVIVAL THERAPIES Cholangiocarcinoma Chemotherapy Surgery Survival Therapies
  • 相关文献

参考文献34

  • 1Ralf-T. Hoffmann,Philipp M. Paprottka,Agnes Sch?n,Fabian Bamberg,Alexander Haug,Eva-Maria Dürr,Barbara Rauch,Christoph T. Trumm,Tobias F. Jakobs,Thomas K. Helmberger,Maximilian F. Reiser,Frank T. Kolligs.Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival[J]. CardioVascular and Interventional Radiology . 2012 (1)
  • 2Akshat Saxena BMedSc,Lourens Bester MBChB, BSc (Hons), FRANZCR,Terence C. Chua BSc (Med) (Hons),Francis C. Chu MBBS, FRACS,David L. Morris MD, PhD.Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option[J]. Annals of Surgical Oncology . 2010 (2)
  • 3YH Shaib,HB El-Serag,JA Davila,R Morgan,KA McGlynn.Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology . 2005
  • 4I Endo,M Gonen,Ac Yopp.Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionAnnals of Surgery,2008.
  • 5Farges O,Fuks D,Le Treut YP,Azoulay D,Laurent A,Ba- chellier P,Nuzzo G,Belghiti J,Pruvot FR,Regimbeau JM.AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholan- giocarcinoma: By the AFC-IHCC-2009 study group. Cancer . 2011
  • 6CW Hammill,LL Wong.Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. Journal of the American College of Surgeons . 2008
  • 7Saiura A,Yamamoto J,Kokudo N,Koga R,Seki M,Hiki N,Yamada K,Natori T,Yamaguchi T.Intrahepatic chol- angiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. The American Journal of Surgery . 2011
  • 8Friman S.Cholangiocarcinoma--current treatment options. Scand J Surg . 2011
  • 9Lang H,Sotiropoulos GC,Sgourakis G, et al.Operations for intrahepatic cholangiocarcinoma:single-institution experience of 158 patients. Journal of the American College of Surgeons . 2009
  • 10Valle JW,Wasan H,Johnson P,Jones E,Dixon L,Swindell R,Baka S,Maraveyas A,Corrie P,Falk S,Gollins S,Lofts F,Ev- ans L,Meyer T,Anthoney A,Iveson T,Highley M,Osborne R,Bridgewater J.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangio- carcinomas or other biliary tract tumours: a multicentre ran- domised phase II study - The UK ABC-01 Study. British Journal of Cancer . 2009

共引文献11

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部